Phase II Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2015
At a glance
- Drugs Aldesleukin (Primary) ; Bevacizumab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 26 Jun 2012 Planned end date changed from 1 Mar 2007 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 15 Nov 2007 Status changed from suspended to in progress.